https://www.jennerex.com/
Jennerex Therapeutics: Best-in-class,oncolytic immunotherapy products for cancer
Jennerex Biotherapeutics develops targeted oncolytic immunotherapies. Pexa-Vec (JX-594) is in Phase 2 trials for HCC, CRC, and RCC.
best in classproducts forjennerextherapeuticsoncolytic
https://www.newswire.ca/news-releases/jennerex-announces-first-patient-treated-in-phase-2-clinical-trial-of-intravenous-delivery-jx-594-in-patients-with-advanced-liver-cancer-510507971.html
Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594...
/CNW/ - Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted...